NF-kappaB Decoy

DB05559InvestigationalSmall molecule

Investigated for use/treatment in atopic dermatitis, inflammatory disorders (unspecified), and skin infections/disorders.

Primary indication
Investigated for use/treatment in atopic dermatitis, inflammatory disorders (unspecified), and skin infections/disorders.Curator reviewed
Also known as
NF-KB Decoy

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of NF-kappaB Decoy, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In